Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) last traded at ₹59, a market capitalisation of ₹218 crore. Over the past 52 weeks the stock has ranged between ₹43 and ₹82. Oxygenta Pharmaceutical Ltd last reported results for the quarter ended Jun 2026, with sales of ₹37 crore and net profit of ₹-2.1 crore. Figures are as of 25 Aug 2026 and are not real time.
Oxygenta Pharmaceutical Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Oxygenta Pharmaceutical Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹37 cr, up 144.5% from ₹15.13 cr a year earlier. Net profit was ₹-2.1 cr, up 65.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14.01 | 33.21 | 49.47 | 15.13 | 14.3 | 33.93 | 49.61 | 37 |
| Expenses | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating profit | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 | 0.55 |
| OPM % | -15.49% | -13.13% | -3.40% | -45.14% | -31.96% | -12.02% | 0.24% | 1.49% |
| Other income | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0 | 0.17 | 0.02 |
| Interest | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 |
| Profit before tax | -2.77 | -4.97 | -3.8 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax % | 2.89% | -20.72% | -43.42% | -25.03% | -23.45% | -23.38% | 32.81% | -15.94% |
| Net profit | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.7 | -2.1 |
| EPS (₹) | -0.80 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 | -0.57 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Oxygenta Pharmaceutical Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Operating profit | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | 7% | 2.4% | -23% | -24% | -9% | -14% | -6% |
| Net profit | 3 | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS (₹) | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
TTM is the trailing twelve months to the most recent quarter.
Oxygenta Pharmaceutical Ltd growth and returns
- 10 Years
- 25%
- 5 Years
- 17%
- 3 Years
- 54%
- TTM
- 21%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -28%
- TTM
- 8%
- 10 Years
- 19%
- 5 Years
- 12%
- 3 Years
- 22%
- 1 Year
- -25%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Oxygenta Pharmaceutical Ltd shareholding pattern
Promoters held 56.53% at Jun 2026, down from 57.95% at Jun 2025. DIIs 0.03%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.28% | 51.12% | 51.12% | 57.95% | 57.95% | 55.93% | 56.53% | 56.53% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Public | 46.69% | 48.84% | 48.84% | 42.02% | 42.01% | 44.05% | 43.44% | 43.43% |
| No. of shareholders | 10,154 | 10,107 | 10,030 | 10,094 | 10,179 | 10,215 | 10,205 | 10,196 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Oxygenta Pharmaceutical Ltd corporate filings
- Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015.AGM/EGMlow impact
Cruxal's analysis: Oxygenta Pharmaceutical Limited has successfully concluded its 33rd Annual General…
Read the full analysis - Outcome of 33rd Annual General Meeting held on 21.08.2026.AGM/EGMlow impact
Cruxal's analysis: Oxygenta Pharmaceutical Limited has successfully concluded its 33rd Annual General…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Oxygenta Pharmaceutical Ltd
Cruxal reads every Oxygenta Pharmaceutical Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.